Index
1 Neuroendocrine Tumors (NETs) Treatment Market Overview
1.1 Product Overview and Scope of Neuroendocrine Tumors (NETs) Treatment
1.2 Neuroendocrine Tumors (NETs) Treatment Segment by Type
1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Somatostatin Analogs (SSAs)
1.2.3 Targeted Therapy
1.2.4 Other
1.3 Neuroendocrine Tumors (NETs) Treatment Segment by Application
1.3.1 Global Neuroendocrine Tumors (NETs) Treatment Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Neuroendocrine Tumors (NETs) Treatment Market Size Estimates and Forecasts
1.4.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue 2019-2030
1.4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales 2019-2030
1.4.3 Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neuroendocrine Tumors (NETs) Treatment Market Competition by Manufacturers
2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Neuroendocrine Tumors (NETs) Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neuroendocrine Tumors (NETs) Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuroendocrine Tumors (NETs) Treatment, Product Type & Application
2.7 Neuroendocrine Tumors (NETs) Treatment Market Competitive Situation and Trends
2.7.1 Neuroendocrine Tumors (NETs) Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neuroendocrine Tumors (NETs) Treatment Players Market Share by Revenue
2.7.3 Global Neuroendocrine Tumors (NETs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuroendocrine Tumors (NETs) Treatment Retrospective Market Scenario by Region
3.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neuroendocrine Tumors (NETs) Treatment Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2019-2030
3.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2019-2024
3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2025-2030
3.3 Global Neuroendocrine Tumors (NETs) Treatment Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2019-2030
3.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2019-2024
3.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2025-2030
3.4 North America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
3.4.1 North America Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2019-2030)
3.4.3 North America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
3.5.1 Europe Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2019-2030)
3.5.3 Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
3.7.1 Latin America Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2019-2030)
3.7.3 Latin America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2019-2030)
4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2019-2024)
4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2025-2030)
4.1.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2019-2030)
4.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2019-2030)
4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2019-2024)
4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2025-2030)
4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2019-2030)
5.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2019-2024)
5.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2025-2030)
5.1.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2019-2030)
5.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2019-2030)
5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2019-2024)
5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2025-2030)
5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Advanced Accelerator Applications
6.1.1 Advanced Accelerator Applications Corporation Information
6.1.2 Advanced Accelerator Applications Description and Business Overview
6.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.1.5 Advanced Accelerator Applications Recent Developments/Updates
6.2 AVEO Oncology
6.2.1 AVEO Oncology Corporation Information
6.2.2 AVEO Oncology Description and Business Overview
6.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.2.5 AVEO Oncology Recent Developments/Updates
6.3 Boehringer Ingelheim International
6.3.1 Boehringer Ingelheim International Corporation Information
6.3.2 Boehringer Ingelheim International Description and Business Overview
6.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.3.5 Boehringer Ingelheim International Recent Developments/Updates
6.4 Hutchison MediPharma Limited
6.4.1 Hutchison MediPharma Limited Corporation Information
6.4.2 Hutchison MediPharma Limited Description and Business Overview
6.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.4.5 Hutchison MediPharma Limited Recent Developments/Updates
6.5 IpsenPharma
6.5.1 IpsenPharma Corporation Information
6.5.2 IpsenPharma Description and Business Overview
6.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.5.5 IpsenPharma Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Pfizer, Inc
6.6.1 Pfizer, Inc Corporation Information
6.6.2 Pfizer, Inc Description and Business Overview
6.6.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.7.5 Pfizer, Inc Recent Developments/Updates
6.8 Progenics Pharmaceuticals
6.8.1 Progenics Pharmaceuticals Corporation Information
6.8.2 Progenics Pharmaceuticals Description and Business Overview
6.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
6.8.5 Progenics Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuroendocrine Tumors (NETs) Treatment Industry Chain Analysis
7.2 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuroendocrine Tumors (NETs) Treatment Production Mode & Process
7.4 Neuroendocrine Tumors (NETs) Treatment Sales and Marketing
7.4.1 Neuroendocrine Tumors (NETs) Treatment Sales Channels
7.4.2 Neuroendocrine Tumors (NETs) Treatment Distributors
7.5 Neuroendocrine Tumors (NETs) Treatment Customers
8 Neuroendocrine Tumors (NETs) Treatment Market Dynamics
8.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
8.2 Neuroendocrine Tumors (NETs) Treatment Market Drivers
8.3 Neuroendocrine Tumors (NETs) Treatment Market Challenges
8.4 Neuroendocrine Tumors (NETs) Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer